← All trials
NCT04915183
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 7, 2021
- Primary completion
- Mar 1, 2025
- Completion date
- Dec 31, 2025
- First posted
- Jun 7, 2021
- Last posted
- Dec 2, 2021
- Enrollment
- 414
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- National Institute on Deafness and Other Communication Disorders (NIDCD)Lead sponsor
- National Institute on Deafness and Other Communication Disorders (NIDCD)Overall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.